Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.

Bertoli S, Tavitian S, Picard M, Huguet F, Vergez F, Delabesse E, Sarry A, Bérard E, Récher C.

Leuk Res. 2018 Dec;75:7-10. doi: 10.1016/j.leukres.2018.10.015. Epub 2018 Oct 31. No abstract available.

PMID:
30419550
2.

Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.

Bertoli S, Paubelle E, Bérard E, Saland E, Thomas X, Tavitian S, Larcher MV, Vergez F, Delabesse E, Sarry A, Huguet F, Larrue C, Bosc C, Farge T, Sarry JE, Michallet M, Récher C.

Eur J Haematol. 2018 Oct 16. doi: 10.1111/ejh.13183. [Epub ahead of print]

PMID:
30325535
3.

Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.

Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C; French Innovative Leukemia Organization.

J Clin Oncol. 2018 Sep 27:JCO2018787366. doi: 10.1200/JCO.2018.78.7366. [Epub ahead of print]

PMID:
30260758
4.

FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.

Perry M, Bertoli S, Rocher C, Hayette S, Ducastelle S, Barraco F, Labussière-Wallet H, Salles G, Recher C, Thomas X, Paubelle E.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):e545-e550. doi: 10.1016/j.clml.2018.06.006. Epub 2018 Jun 13.

PMID:
30082225
5.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

Adès L, Thomas X, Guerci Bresler A, Raffoux E, Spertini O, Vey N, Marchand T, Récher C, Pigneux A, Girault S, Deconinck E, Gardin C, Tournilhac O, Lambert JF, Chevallier P, de Botton S, Lejeune J, Dombret H, Chevret S, Fenaux P; French Belgian Swiss APL group.

Haematologica. 2018 Jul 19. pii: haematol.2018.198614. doi: 10.3324/haematol.2018.198614. [Epub ahead of print]

6.

Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey.

Bories P, Lamy S, Simand C, Bertoli S, Delpierre C, Malak S, Fornecker L, Moreau S, Récher C, Nebout A.

Haematologica. 2018 Jul 13. pii: haematol.2018.192468. doi: 10.3324/haematol.2018.192468. [Epub ahead of print]

7.

Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.

Bertoli S, Tavitian S, Berard E, Gadaud N, Luquet I, Huynh A, Sarry A, Huguet F, Récher C.

Leuk Lymphoma. 2018 Jun 12:1-4. doi: 10.1080/10428194.2018.1464156. [Epub ahead of print] No abstract available.

PMID:
29893611
8.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24. No abstract available.

9.

NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.

Prata PH, Bally C, Prebet T, Recher C, Venton G, Thomas X, Raffoux E, Pigneux A, Cluzeau T, Desoutter J, Gay J, Preudhomme C, Fenaux P, Adès L.

Haematologica. 2018 Oct;103(10):e455-e457. doi: 10.3324/haematol.2018.189886. Epub 2018 May 10. No abstract available.

10.

Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning.

Hindié E, Récher C, Zerdoud S, Leenhardt L, Avram AM.

J Clin Oncol. 2018 Jun 20;36(18):1881-1882. doi: 10.1200/JCO.2018.78.1096. Epub 2018 May 3. No abstract available.

PMID:
29723097
11.

DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.

Grgurevic S, Montilla-Perez P, Bradbury A, Gilhodes J, Queille S, Pelofy S, Bancaud A, Filleron T, Ysebaert L, Récher C, Laurent G, Fournié JJ, Cazaux C, Quillet-Mary A, Hoffmann JS.

Haematologica. 2018 Jun;103(6):1038-1046. doi: 10.3324/haematol.2017.174243. Epub 2018 Mar 22.

12.

Dexamethasone in hyperleukocytic acute myeloid leukemia.

Bertoli S, Picard M, Bérard E, Griessinger E, Larrue C, Mouchel PL, Vergez F, Tavitian S, Yon E, Ruiz J, Delabesse E, Luquet I, Linares LK, Saland E, Carroll M, Danet-Desnoyers G, Sarry A, Huguet F, Sarry JE, Récher C.

Haematologica. 2018 Jun;103(6):988-998. doi: 10.3324/haematol.2017.184267. Epub 2018 Mar 8.

13.

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H.

BMC Cancer. 2017 Dec 14;17(1):852. doi: 10.1186/s12885-017-3803-6.

14.

Dendrogenin A drives LXR to trigger lethal autophagy in cancers.

Segala G, David M, de Medina P, Poirot MC, Serhan N, Vergez F, Mougel A, Saland E, Carayon K, Leignadier J, Caron N, Voisin M, Cherier J, Ligat L, Lopez F, Noguer E, Rives A, Payré B, Saati TA, Lamaziere A, Despres G, Lobaccaro JM, Baron S, Demur C, de Toni F, Larrue C, Boutzen H, Thomas F, Sarry JE, Tosolini M, Picard D, Record M, Récher C, Poirot M, Silvente-Poirot S.

Nat Commun. 2017 Dec 4;8(1):1903. doi: 10.1038/s41467-017-01948-9.

15.

Improved outcome for AML patients over the years 2000-2014.

Bertoli S, Tavitian S, Huynh A, Borel C, Guenounou S, Luquet I, Delabesse E, Sarry A, Laurent G, Attal M, Huguet F, Bérard E, Récher C.

Blood Cancer J. 2017 Nov 29;7(12):635. doi: 10.1038/s41408-017-0011-1.

16.

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia.

Dumas PY, Bertoli S, Bérard E, Médiavilla C, Yon E, Tavitian S, Leguay T, Huguet F, Forcade E, Milpied N, Sarry A, Sauvezie M, Bories P, Pigneux A, Récher C.

Oncotarget. 2017 Mar 7;8(45):79126-79136. doi: 10.18632/oncotarget.15988. eCollection 2017 Oct 3.

17.

Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance.

David L, Manenti S, Récher C, Hoffmann JS, Didier C.

Mol Cell Oncol. 2017 Sep 18;4(5):e1289293. doi: 10.1080/23723556.2017.1289293. eCollection 2017.

18.

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.

Besson C, Lancar R, Prevot S, Algarte-Genin M, Delobel P, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Boue F, Coppo P, Costello R, Hendel-Chavez H, Mekerri N, Dos Santos G, Recher C, Delarue R, Casasnovas RO, Taoufik Y, Mounier N, Costagliola D; ANRS-CO16 LYMPHOVIR Cohort.

AIDS. 2017 Nov 28;31(18):2493-2501. doi: 10.1097/QAD.0000000000001652.

PMID:
28926410
19.

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J.

Leukemia. 2018 Mar;32(3):597-605. doi: 10.1038/leu.2017.284. Epub 2017 Sep 15.

PMID:
28914261
20.

Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy.

Comont T, Tavitian S, Bardiaux L, Fort M, Debiol B, Morère D, Bérard E, Delabesse E, Luquet I, Martinez S, Huguet F, Récher C, Bertoli S.

Leuk Res. 2017 Oct;61:62-67. doi: 10.1016/j.leukres.2017.08.015. Epub 2017 Aug 30.

PMID:
28910610
21.

Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.

De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S, Demur C, Delabesse E, Recher C, Touriol C, Martelli MP, Falini B, Brousset P, Bousquet M.

Haematologica. 2017 Oct;102(10):1718-1726. doi: 10.3324/haematol.2017.171645. Epub 2017 Jul 4.

22.

Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia.

Bétrian S, Guenounou S, Luquet I, Demur C, Huynh A, Ysebaert L, Recher C, Huguet F.

Hematol Oncol. 2017 Jun;35(2):252-255. doi: 10.1002/hon.2252. Epub 2015 Oct 8.

PMID:
28620927
23.

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.

Hunault-Berger M, Maillard N, Himberlin C, Recher C, Schmidt-Tanguy A, Choufi B, Bonmati C, Carré M, Couturier MA, Daguindau E, Marolleau JP, Orsini-Piocelle F, Delaunay J, Tavernier E, Lissandre S, Ojeda-Uribe M, Sanhes L, Sutton L, Banos A, Fornecker LM, Bernard M, Bouscary D, Saad A, Puyade M, Rouillé V, Luquet I, Béné MC, Hamel JF, Dreyfus F, Ifrah N, Pigneux A.

Blood Cancer J. 2017 Jun 2;7(6):e568. doi: 10.1038/bcj.2017.50. No abstract available.

24.

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, Féliu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais JC, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, Récher C, Sarry JE.

Cancer Discov. 2017 Jul;7(7):716-735. doi: 10.1158/2159-8290.CD-16-0441. Epub 2017 Apr 17.

25.

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.

Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N.

Leukemia. 2017 Nov;31(11):2326-2335. doi: 10.1038/leu.2017.81. Epub 2017 Mar 10.

PMID:
28280275
26.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H.

J Clin Oncol. 2017 Apr 10;35(11):1223-1230. doi: 10.1200/JCO.2016.70.4551. Epub 2017 Feb 21.

PMID:
28221862
27.

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.

Pigneux A, Béné MC, Guardiola P, Recher C, Hamel JF, Sauvezie M, Harousseau JL, Tournilhac O, Witz F, Berthou C, Escoffre-Barbe M, Guyotat D, Fegueux N, Himberlin C, Hunault M, Delain M, Lioure B, Jourdan E, Bauduer F, Dreyfus F, Cahn JY, Sotto JJ, Ifrah N.

J Clin Oncol. 2017 Feb;35(4):387-393. doi: 10.1200/JCO.2016.67.6213. Epub 2016 Oct 24.

PMID:
28129526
28.

Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.

Cahu X, Carré M, Recher C, Pigneux A, Hunault-Berger M, Vey N, Chevallier P, Delaunay J, Gyan E, Lioure B, Bonmati C, Himberlin C, Hicheri Y, Guillerm G, Didier B, Larosa F, Ojeda-Uribe M, Bernard M, Bene MC, Ifrah N, Cahn JY.

Eur J Haematol. 2017 May;98(5):443-449. doi: 10.1111/ejh.12850. Epub 2017 Mar 1.

PMID:
28122150
29.

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.

Ades L, Prebet T, Stamatoullas A, Recher C, Guieze R, Raffoux E, Bouabdallah K, Hunault M, Wattel E, Stalnikiewicz L, Toma A, Dombret H, Vey N, Sebert M, Gardin C, Chaffaut C, Chevret S, Fenaux P.

Haematologica. 2017 Apr;102(4):728-735. doi: 10.3324/haematol.2016.151894. Epub 2016 Dec 29.

30.

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.

Vey N, Prebet T, Thalamas C, Charbonnier A, Rey J, Kloos I, Liu E, Luan Y, Vezan R, Graef T, Recher C.

Leuk Lymphoma. 2017 Aug;58(8):1880-1886. doi: 10.1080/10428194.2016.1263843. Epub 2016 Dec 2.

PMID:
27911138
31.

Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response.

Guenounou S, Borel C, Bérard E, Yon E, Fort M, Mengelle C, Bertoli S, Sarry A, Tavitian S, Huguet F, Attal M, Récher C, Huynh A.

Medicine (Baltimore). 2016 Nov;95(48):e5356.

32.

Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia.

Cerella C, Gaigneaux A, Mazumder A, Lee JY, Saland E, Radogna F, Farge T, Vergez F, Récher C, Sarry JE, Kim KW, Shin HY, Dicato M, Diederich M.

Leukemia. 2017 Mar;31(3):755-759. doi: 10.1038/leu.2016.341. Epub 2016 Nov 22. No abstract available.

33.

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.

Bertoli S, Sterin A, Tavitian S, Oberic L, Ysebaert L, Bouabdallah R, Vergez F, Sarry A, Bérard E, Huguet F, Laurent G, Prébet T, Vey N, Récher C.

Oncotarget. 2016 Dec 27;7(52):85937-85947. doi: 10.18632/oncotarget.13262.

34.

CHK1 as a therapeutic target to bypass chemoresistance in AML.

David L, Fernandez-Vidal A, Bertoli S, Grgurevic S, Lepage B, Deshaies D, Prade N, Cartel M, Larrue C, Sarry JE, Delabesse E, Cazaux C, Didier C, Récher C, Manenti S, Hoffmann JS.

Sci Signal. 2016 Sep 13;9(445):ra90. doi: 10.1126/scisignal.aac9704.

PMID:
27625304
35.

The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study.

Lamy S, Bettiol C, Grosclaude P, Compaci G, Albertus G, Récher C, Nogaro JC, Despas F, Laurent G, Delpierre C.

BMC Health Serv Res. 2016 Aug 2;16(a):336. doi: 10.1186/s12913-016-1553-9.

36.

3R gene expression in chronic lymphocytic leukemia reveals insight into disease evolution.

Grgurevic S, Berquet L, Quillet-Mary A, Laurent G, Récher C, Ysebaert L, Cazaux C, Hoffmann JS.

Blood Cancer J. 2016 Jun 3;6(6):e429. doi: 10.1038/bcj.2016.39. No abstract available.

37.

Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy.

Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, Saland E, Castellano R, Pouyet L, Collette Y, Vey N, Chabannon C, Recher C, Sarry JE, Alcor D, Peyron JF, Griessinger E.

Blood. 2016 Jul 14;128(2):253-64. doi: 10.1182/blood-2015-07-655860. Epub 2016 Jun 2.

38.

Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.

Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, Legoff M, Biau D, Anract P, Roux C, Blanc-Autran E, Delarue R, Gisselbrecht C, Ketterer N, Recher C, Bonnet C, Peyrade F, Haioun C, Tilly H, Salles G, Brice P, Bouscary D, Deau B, Tamburini J.

Leuk Lymphoma. 2016 Dec;57(12):2820-2826. Epub 2016 Apr 27. Erratum in: Leuk Lymphoma. 2017 Feb;58(2):507-508.

39.

Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib.

Branco B, Metsu D, Dutertre M, Marchou B, Delobel P, Recher C, Martin-Blondel G.

Ann Hematol. 2016 Jun;95(7):1207-9. doi: 10.1007/s00277-016-2684-0. Epub 2016 Apr 26. No abstract available.

PMID:
27113251
40.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.

Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, Gomez-Roca C, Papayannidis C, Kebenko M, Paschka P, Christen R, Guarin E, Bröske AM, Baehner M, Brewster M, Walz AC, Michielin F, Runza V, Meresse V, Recher C.

Oncotarget. 2016 May 31;7(22):32532-42. doi: 10.18632/oncotarget.8687.

41.

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.

Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G.

Lancet. 2016 Jun 11;387(10036):2402-11. doi: 10.1016/S0140-6736(15)01317-3. Epub 2016 Apr 11.

PMID:
27080498
42.

A Systemic Capillary Leak Syndrome (Clarkson Syndrome) in a Patient with Chronic Lymphocytic Leukemia: A Case Report in an Out-of-Hospital Setting.

Durand Bechu M, Rouget A, Recher C, Azoulay E, Bounes V.

Case Rep Emerg Med. 2016;2016:5347039. doi: 10.1155/2016/5347039. Epub 2016 Mar 16.

43.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.

Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, Taussig DC, Rezai K, Roumier C, Herait P, Kahatt C, Quesnel B, Michallet M, Recher C, Lokiec F, Preudhomme C, Dombret H.

Lancet Haematol. 2016 Apr;3(4):e186-95. doi: 10.1016/S2352-3026(15)00247-1. Epub 2016 Mar 18.

PMID:
27063977
44.

Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.

Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, Riscal R, Yang G, Hirsch P, David M, De Mas-Mansat V, Delabesse E, Vallar L, Delhommeau F, Jouanin I, Ouerfelli O, Le Cam L, Linares LK, Junot C, Portais JC, Vergez F, Récher C, Sarry JE.

J Exp Med. 2016 Apr 4;213(4):483-97. doi: 10.1084/jem.20150736. Epub 2016 Mar 7.

45.

Bone marrow tryptase as a possible diagnostic criterion for adult systemic mastocytosis.

Bulai Livideanu C, Apoil PA, Lepage B, Eischen M, Laurent C, Laharrague P, Lamant L, Tournier E, Tavitian S, Pouplard C, Recher C, Laroche M, Mailhol C, Dubreuil P, Hermine O, Blancher A, Paul C.

Clin Exp Allergy. 2016 Jan;46(1):133-41. doi: 10.1111/cea.12627.

PMID:
26767494
46.

CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.

Bertoli S, Boutzen H, David L, Larrue C, Vergez F, Fernandez-Vidal A, Yuan L, Hospital MA, Tamburini J, Demur C, Delabesse E, Saland E, Sarry JE, Galcera MO, Mansat-De Mas V, Didier C, Dozier C, Récher C, Manenti S.

Oncotarget. 2015 Nov 10;6(35):38061-78. doi: 10.18632/oncotarget.5706.

47.

Impact of obesity in favorable-risk AML patients receiving intensive chemotherapy.

Tavitian S, Denis A, Vergez F, Berard E, Sarry A, Huynh A, Delabesse E, Luquet I, Huguet F, Récher C, Bertoli S.

Am J Hematol. 2016 Feb;91(2):193-8. doi: 10.1002/ajh.24228. Epub 2015 Nov 26.

48.

Ambulatory Medical Assistance--After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy.

Compaci G, Rueter M, Lamy S, Oberic L, Recher C, Lapeyre-Mestre M, Laurent G, Despas F.

BMC Cancer. 2015 Oct 24;15:781. doi: 10.1186/s12885-015-1815-7.

49.

Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature.

Masson Regnault M, Gadaud N, Boulinguez S, Tournier E, Lamant L, Gladieff L, Roche H, Guenounou S, Recher C, Sibaud V.

Dermatology. 2015;231(4):312-8. doi: 10.1159/000439047. Epub 2015 Oct 1. Review.

PMID:
26422424
50.

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jäkel N, Gopalakrishna P, McQuitty M, Stalbovskaya V, Recher C, Theunissen K, Gisslinger H, Kiladjian JJ, Al-Ali HK.

Exp Hematol Oncol. 2015 Sep 15;4:26. doi: 10.1186/s40164-015-0021-2. eCollection 2015.

Supplemental Content

Loading ...
Support Center